.RESEARCH STUDY FEATURE.06 August 2024.
A sizable randomized regulated trial with cisgender females highlights the difficulties of fidelity to a day-to-day oral preexposure treatment routine as well as illustrates that twice-yearly injection of lenacapavir can easily sustain effective HIV deterrence degrees over 6 months.